You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)與PPI簽署更新信貸融資函件
格隆匯 02-11 18:35

格隆匯2月11日丨李氏大藥廠(00950.HK)公佈,2020年2月11日,公司與PPI簽署更新信貸融資函件,據此,公司確認提供擔保(以該銀行為受益人),負責償還PPI根據更新信貸融資而結欠該銀行的一切有抵押債務。

根據更新信貸融資函件,該銀行同意向PPI提供更新信貸融資,包括一筆最多為1300萬港元的循環貸款融資、一筆最多為4000萬港元的需要貸款融資及一筆最多為600萬港元的透支信貸額,但透支信貸融資及循環貸款融資的尚未償還總額在任何時間均不可超逾1300萬港元。

PPI於2009年8月6日在英屬處女羣島註冊成立,現時經營業務為生產、開發及銷售Zingo及其平台,以及隨附的粉狀皮下注射系統和其他醫療設備(如開發連續式血糖監測儀),其由公司間接持股33.92%。

公司稱,PPI現時正在擴充業務,其中包括生產、開發及推廣銷售醫療設備。為確保業務能夠藉着充足的財務資源而穩定增長,PPI需要現金流以擴充業務,其中包括生產、開發及推廣銷售醫療設備。公司就更新信貸融資提供擔保可容許PPI獲得更多財務資源,以進行發展及生產新醫療設備,從而為公司(作為PPI的股東之一)帶來更佳的投資回報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account